Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B

A Phase III Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00131742

Enrollment

Unknown

Registered

2005-08-19

Start date

2004-07-31

Completion date

2007-01-31

Last updated

2015-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis B

Brief summary

This study is being conducted to compare the effectiveness and safety of telbivudine (LdT) and lamivudine in Chinese adults.

Interventions

DRUGtelbivudine

DRUGlamivudine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

16 Years to 70 Years

Inclusion criteria

* Documented clinical history compatible with chronic hepatitis B infection Other protocol-defined inclusion criteria may apply

Exclusion criteria

* Patient is pregnant or breastfeeding * Patient is co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV) or HIV * Patient has previously received lamivudine or any investigational anti-HBV nucleoside or nucleotide analog Other protocol-defined

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026